The Food and Drug Administration (FDA) recently authorized the initial CRISPR-based gene therapy for sickle cell disease called ‘BIRSA 101’. The new breakthrough enables a potential cure through direct gene correction of faulty sequences. The advancement shows how gene editing continues to transform the direction of personalized healthcare. The present reality surpasses innovation as it exists presently.
MBH/PS